Address correspondence to Kevin A. Schulman, M.D., Center for Clinical and Genetic Economics, Duke Clinical Research Institute, P.O. Box 17969, Durham, NC 27715. Dr. Lesley H. Curtis, Dr. Kevin A. Schulman, Ms. Jasmina I. Radeva, and Ms. Jennifer Stoddard are with the Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC. Ms. Jasmina I. Radeva is now with Analysis Group, Boston, MA. Dr. Steve Hutchison is with AdvancePCS, Scottsdale, AZ and is now with Health Services Advisory Group, Phoenix, AZ. Drs. Peter E. Dans and Alan Wright are with AdvancePCS Clinical Services, Hunt Valley, MD. Dr. Peter E. Dans is now an independent consultant. Dr. Alan Wright is now with Resolution Health, Inc., San Jose, CA. Dr. Raymond L. Woosley is with the University of Arizona Health Sciences Center, Tucson, AZ.
1475-6773/asset/HESR_left.gif?v=1&s=e1aefc6479f5e5bfb0939ee5cf47664a10a5284c)
1475-6773/asset/HESR_centre.gif?v=1&s=214ade28bc6ce575c2996d5bbf437466f695ada9)
1475-6773/asset/HESR_right.gif?v=1&s=b41919a083fd565ed8cb6b14c656f8af2160073b)
Geographic Variation in the Prescription of Schedule II Opioid Analgesics among Outpatients in the United States
Article first published online: 21 FEB 2006
DOI: 10.1111/j.1475-6773.2006.00511.x
Additional Information
How to Cite
Curtis, L. H., Stoddard, J., Radeva, J. I., Hutchison, S., Dans, P. E., Wright, A., Woosley, R. L. and Schulman, K. A. (2006), Geographic Variation in the Prescription of Schedule II Opioid Analgesics among Outpatients in the United States. Health Services Research, 41: 837–855. doi: 10.1111/j.1475-6773.2006.00511.x
Publication History
- Issue published online: 21 FEB 2006
- Article first published online: 21 FEB 2006
- Abstract
- Article
- References
- Cited By
Keywords:
- Analgesics;
- opioid;
- health services accessibility;
- oxycodone
Objective. To measure geographic variation in opioid use in a large, commercially insured, outpatient population in the United States.
Data Sources. Outpatient prescription drug claims database of a national pharmaceutical benefit manager for 7,873,337 subjects with at least one prescription drug claim in 2000.
Study Design. We measured the period prevalence of claims for opioid analgesics and controlled-release oxycodone at the state level. We measured geographic variation using the weighted coefficient of variation and systematic component of variation. In county-level multivariable regression, we explored associations between potential explanatory variables and claims for opioid analgesics and controlled-release oxycodone.
Principal Findings. A total of 567,778 (64.2 per 1,000 total claims) were for oral opioid analgesics. Claim rates by state ranged from <20 to >100 claims per 1,000 total claims. States with long-standing prescription monitoring programs had among the lowest rates. In the county-level data, presence of a statewide prescription monitoring program and proportions of the population aged 15–24 and 65 years and older were independently and negatively associated with claim rates for all opioid analgesics. Surgeons per 1,000, proportion of the population reporting illicit drug use, and proportion who were female were independently and positively associated with claim rates for all opioid analgesics. Only the proportion of the population aged 25–34 and number of surgeons per 1,000 were independently and positively associated with claim rates for oxycodone.
Conclusions. Claim rates for opioid analgesics vary significantly by state. Presence of a statewide prescription monitoring program is associated with lower claim rates at the county level. Future research should use individual-level data to assess whether these findings reflect a reduction in abuse and diversion or suboptimal treatment of pain.